-
Mashup Score: 5Anakinra for refractory CRS or ICANS after CAR T-cell therapy - 1 year(s) ago
Chimeric antigen receptor-engineered (CAR) T-cell therapy remains limited by significant toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). The optimal management of severe and/or refractory CRS/ICANS remains ill-defined. Anakinra has emerged as a promising agent based on preclinical data, but its safety and efficacy in CAR…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Anakinra for refractory CRS or ICANS after CAR T-cell therapy - 1 year(s) ago
Chimeric antigen receptor-engineered (CAR) T-cell therapy remains limited by significant toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). The optimal management of severe and/or refractory CRS/ICANS remains ill-defined. Anakinra has emerged as a promising agent based on preclinical data, but its safety and efficacy in CAR…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 4
The use of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis, which is standard practice with haploidentical hematopoietic cell transplantations (HCT), is now becoming the standard of care for patients undergoing HLA-matched unrelated donor (MUD) HCT with reduced-intensity conditioning (RIC).1,2 An analysis of the Center for International Blood and Marrow…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
The use of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis, which is standard practice with haploidentical hematopoietic cell transplantations (HCT), is now becoming the standard of care for patients undergoing HLA-matched unrelated donor (MUD) HCT with reduced-intensity conditioning (RIC).1,2 An analysis of the Center for International Blood and Marrow…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0
CD19-targeted chimeric antigen receptor T cell (CAR-T) therapies have transformed the treatment landscape for patients with relapsed/refractory B cell lymphoma [1–3]. However, up to 60% of patients will not achieve a complete response (CR) following CAR-T therapy, and unfortunately for such patients, the median duration of response is as short as 2 months [3]. Thus, approximately two-thirds of…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0
Despite improved treatment outcomes for non-Hodgkin lymphoma (NHL), the prognosis remains poor, with an unmet need for novel therapies [1]. Rituximab is the cornerstone for treating B cell NHL, and attempts have been made to enhance its clinical benefits by combining it with chemotherapy or cell therapy, such as natural killer (NK) cell treatment. Rituximab is used for antibody-dependent…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely new approach was taken with the goal of better serving clinical providers by…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy - 1 year(s) ago
Our previous clinical study showed that patients with refractory/relapsed (r/r) T cell acute lymphoblastic leukemia (T-ALL) achieved 90% complete remission (CR) with donor-derived CD7 chimeric antigen receptor T cell (CAR-T) therapy, but some patients developed donor-recipient mixed chimerism and remarkable pancytopenia [1]. Lu et al. [2] also reported the efficacy and safety of CD7 CAR-T. T cell…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma - 1 year(s) ago
Over the past decade, therapeutic options in multiple myeloma (MM) have changed dramatically. Given the unprecedented efficacy of novel agents, the role of hematopoietic cell transplantation (HCT) in MM remains under scrutiny. Rapid advances in myeloma immunotherapy including the recent approval of chimeric antigen receptor (CAR) T-cell therapy will impact the MM therapeutic landscape. The…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASTCTChat Q7: Does the clinical trial enrollment of this population skew these data towards higher QoL than the general older transplant population?https://t.co/kgBOAbvffh https://t.co/3eKroUK34f
-
Anakinra for refractory CRS or ICANS after CAR T-cell therapy https://t.co/NAF55IYvOu